These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
296 related articles for article (PubMed ID: 28523942)
1. Combinatorial therapeutic approaches with RNAi and anticancer drugs using nanodrug delivery systems. Babu A; Munshi A; Ramesh R Drug Dev Ind Pharm; 2017 Sep; 43(9):1391-1401. PubMed ID: 28523942 [TBL] [Abstract][Full Text] [Related]
2. Quick synthesis of a novel combinatorial delivery system of siRNA and doxorubicin for a synergistic anticancer effect. Chen M; Wang L; Wang F; Li F; Xia W; Gu H; Chen Y Int J Nanomedicine; 2019; 14():3557-3569. PubMed ID: 31190812 [No Abstract] [Full Text] [Related]
3. Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances. Gandhi NS; Tekade RK; Chougule MB J Control Release; 2014 Nov; 194():238-56. PubMed ID: 25204288 [TBL] [Abstract][Full Text] [Related]
4. Nanocarriers for delivery of siRNA and co-delivery of siRNA and other therapeutic agents. Zhao J; Feng SS Nanomedicine (Lond); 2015 Jul; 10(14):2199-228. PubMed ID: 26214357 [TBL] [Abstract][Full Text] [Related]
5. Simultaneous nanocarrier-mediated delivery of siRNAs and chemotherapeutic agents in cancer therapy and diagnosis: Recent advances. Bidar N; Darroudi M; Ebrahimzadeh A; Safdari M; de la Guardia M; Baradaran B; Goodarzi V; Oroojalian F; Mokhtarzadeh A Eur J Pharmacol; 2022 Jan; 915():174639. PubMed ID: 34919890 [TBL] [Abstract][Full Text] [Related]
6. Nanoparticle-mediated delivery of siRNA for effective lung cancer therapy. Kim YD; Park TE; Singh B; Maharjan S; Choi YJ; Choung PH; Arote RB; Cho CS Nanomedicine (Lond); 2015; 10(7):1165-88. PubMed ID: 25929572 [TBL] [Abstract][Full Text] [Related]
7. Aptamer-functionalized hybrid nanoparticle for the treatment of breast cancer. Powell D; Chandra S; Dodson K; Shaheen F; Wiltz K; Ireland S; Syed M; Dash S; Wiese T; Mandal T; Kundu A Eur J Pharm Biopharm; 2017 May; 114():108-118. PubMed ID: 28131717 [TBL] [Abstract][Full Text] [Related]
8. Efficient nanocarriers of siRNA therapeutics for cancer treatment. Subhan MA; Torchilin VP Transl Res; 2019 Dec; 214():62-91. PubMed ID: 31369717 [TBL] [Abstract][Full Text] [Related]
9. Nanoparticle-siRNA: a potential strategy for ovarian cancer therapy? Aghamiri S; Mehrjardi KF; Shabani S; Keshavarz-Fathi M; Kargar S; Rezaei N Nanomedicine (Lond); 2019 Aug; 14(15):2083-2100. PubMed ID: 31368405 [TBL] [Abstract][Full Text] [Related]
10. Therapeutic targeting of siRNA/anti-cancer drug delivery system for non-melanoma skin cancer. Part I: Development and gene silencing of JAK1siRNA/5-FU loaded liposome nanocomplexes. Aslan M; Ozturk S; Shahbazi R; Bozdemir Ö; Dilara Zeybek N; Vargel İ; Eroğlu İ; Ulubayram K Eur J Pharm Biopharm; 2024 Oct; 203():114432. PubMed ID: 39097115 [TBL] [Abstract][Full Text] [Related]
11. Integrated hollow mesoporous silica nanoparticles for target drug/siRNA co-delivery. Ma X; Zhao Y; Ng KW; Zhao Y Chemistry; 2013 Nov; 19(46):15593-603. PubMed ID: 24123533 [TBL] [Abstract][Full Text] [Related]
12. Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges. Gomes-da-Silva LC; Fonseca NA; Moura V; Pedroso de Lima MC; Simões S; Moreira JN Acc Chem Res; 2012 Jul; 45(7):1163-71. PubMed ID: 22568781 [TBL] [Abstract][Full Text] [Related]
13. Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer. Chen Y; Bathula SR; Li J; Huang L J Biol Chem; 2010 Jul; 285(29):22639-50. PubMed ID: 20460382 [TBL] [Abstract][Full Text] [Related]
14. [Cytological Study in vitro on Co-delivery of siRNA and Paclitaxel within Solid Lipid Nanoparticles to Overcome Multidrug Resistance in Tumors]. Huang R; Yao X; Chen Y; Sun X; Lin Y Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2016 Feb; 33(1):108-14. PubMed ID: 27382749 [TBL] [Abstract][Full Text] [Related]
15. Non-viral vectors combined delivery of siRNA and anti-cancer drugs to reverse tumor multidrug resistance. Xue R; Pan Y; Xia L; Li J Biomed Pharmacother; 2024 Sep; 178():117119. PubMed ID: 39142247 [TBL] [Abstract][Full Text] [Related]
16. Reversal of multidrug resistance in vitro by co-delivery of MDR1 targeting siRNA and doxorubicin using a novel cationic poly(lactide-co-glycolide) nanoformulation. Misra R; Das M; Sahoo BS; Sahoo SK Int J Pharm; 2014 Nov; 475(1-2):372-84. PubMed ID: 25178825 [TBL] [Abstract][Full Text] [Related]
17. Effective combination treatment of lung cancer cells by single vehicular delivery of siRNA and different anticancer drugs. Li J; Wang Y; Xue S; Sun J; Zhang W; Hu P; Ji L; Mao Z Int J Nanomedicine; 2016; 11():4609-4624. PubMed ID: 27695321 [TBL] [Abstract][Full Text] [Related]
18. Codelivery of anticancer drugs and siRNA by mesoporous silica nanoparticles. Hanafi-Bojd MY; Ansari L; Malaekeh-Nikouei B Ther Deliv; 2016 Sep; 7(9):649-55. PubMed ID: 27582236 [TBL] [Abstract][Full Text] [Related]
19. The importance of co-delivery of nanoparticle-siRNA and anticancer agents in cancer therapy. Khelghati N; Soleimanpour Mokhtarvand J; Mir M; Alemi F; Asemi Z; Sadeghpour A; Maleki M; Samadi Kafil H; Jadidi-Niaragh F; Majidinia M; Yousefi B Chem Biol Drug Des; 2021 Apr; 97(4):997-1015. PubMed ID: 33458952 [TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo inhibition of MRP gene expression and reversal of multidrug resistance by siRNA. Wu Z; Li X; Zeng Y; Zhuang X; Shen H; Zhu H; Liu H; Xiao H Basic Clin Pharmacol Toxicol; 2011 Mar; 108(3):177-84. PubMed ID: 21073659 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]